MiniMed Group is set to release its Q1 earnings, with analysts significantly lowering their expectations for both EPS and revenue compared to the prior year. Several prominent analysts have recently cut their price targets for MMED, reflecting a more cautious outlook ahead of the earnings report.
MiniMed Group (MMED) is facing a challenging Q1 earnings report, with consensus estimates for EPS at 9 cents, a sharp decline from 35 cents last year, and revenue projected at $828.43 million, down significantly from $3.03 billion. This substantial downgrade in expectations, coupled with multiple analysts cutting their price targets, suggests a negative sentiment surrounding the company's near-term performance. While the stock closed slightly up on Thursday, the revised analyst outlook could pressure shares post-earnings. Traders should be aware of the potential for volatility and a negative reaction if the company misses these already lowered expectations, or if guidance is weaker than anticipated.